Systematic conversion to generic tacrolimus in stable kidney transplant recipients

BACKGROUND: Tacrolimus (Prograf(®)) is a key drug in the immunosuppressive treatment of renal transplant patients. Since the expiration of the patent for Prograf(®), generic preparations have been approved in Europe as bioequivalence has been shown in healthy volunteers. However, few studies have in...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenborg, Staffan, Nordström, Annica, Almquist, Tora, Wennberg, Lars, Bárány, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970341/
https://www.ncbi.nlm.nih.gov/pubmed/24944783
http://dx.doi.org/10.1093/ckj/sfu015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970341/
https://www.ncbi.nlm.nih.gov/pubmed/24944783
http://dx.doi.org/10.1093/ckj/sfu015

Ejemplares similares